← Product Code [KTT](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KTT) · K030372

# MODIFICATION TO EBI DYNAFIX DIAPHYSEAL CORRECTION SYSTEM (K030372)

_Ebi, L.P. · KTT · Mar 6, 2003 · Orthopedic · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KTT/K030372

## Device Facts

- **Applicant:** Ebi, L.P.
- **Product Code:** [KTT](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KTT.md)
- **Decision Date:** Mar 6, 2003
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 888.3030
- **Device Class:** Class 2
- **Review Panel:** Orthopedic
- **Attributes:** Therapeutic

## Intended Use

The EBI® DynaFix® Diaphyseal Correction System is intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.

## Device Story

Unilateral external fixation device; used in conjunction with EBI XFIX DFS System. Bone screws inserted through skin/soft tissue into bone; fixator frame attached to screw shanks. Used by surgeons in clinical settings for orthopedic correction/stabilization. Provides mechanical support for bone healing/alignment; benefits patient via stabilization of fractures or correction of bone deformities.

## Clinical Evidence

No clinical data; bench testing only.

## Technological Characteristics

Unilateral external fixation system. Materials: titanium, stainless steel, aluminum, Delrin®. Mechanical fixation principle. No software or electronic components.

## Regulatory Identification

Single/multiple component metallic bone fixation appliances and accessories are devices intended to be implanted consisting of one or more metallic components and their metallic fasteners. The devices contain a plate, a nail/plate combination, or a blade/plate combination that are made of alloys, such as cobalt-chromium-molybdenum, stainless steel, and titanium, that are intended to be held in position with fasteners, such as screws and nails, or bolts, nuts, and washers. These devices are used for fixation of fractures of the proximal or distal end of long bones, such as intracapsular, intertrochanteric, intercervical, supracondylar, or condylar fractures of the femur; for fusion of a joint; or for surgical procedures that involve cutting a bone. The devices may be implanted or attached through the skin so that a pulling force (traction) may be applied to the skeletal system.

## Predicate Devices

- EBI® DynaFix® Diaphyseal Correction System ([K021695](/device/K021695.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

030372 page 1 of 2

## MAR 0 6 2003 510(k) Summary

This 510(k) Summary for the EB1® DynaFix® Diaphyseal Correction System is provided as required per Section 513(3) of the Food, Drug and Cosmetic Act.

| 1. | Submitter: EBI, L.P.<br>100 Interpace Parkway<br>Parsippany, NJ 07054 | Contact Person: Frederic Testa<br>Phone: (973)299-9300, ext. 2208 |
|----|-----------------------------------------------------------------------|-------------------------------------------------------------------|
|    | Date prepared:                                                        | February 3, 2003                                                  |
| 2. | Proprietary Name:                                                     | EBI® DynaFix® Diaphyseal Correction System                        |
|    | Common Name:                                                          | External Fixation Device                                          |
|    | Classification Names:                                                 | Single/Multiple Component Metallic Bone Fixation                  |
|    |                                                                       | Appliances and Accessories, 21 CFR 888.3030                       |

- 3. Predicate or legally marketed devices that are substantially equivalent:
	- EBI® DynaFix® Diaphyseal Correction System -- EBI, L.P. (K021695) .
- 4. Description of the device: The EBI® DynaFix® Diaphyseal Correction System is a module which is used in conjunction with the currently marketed EBI XFIX DFS System. The System consists of external fixation components and implantable bone screws. The System is utilized in the following manner: bone screws are inserted through the patient's skin and soft tissue and into the bone. The fixator frame of the System is attached to the shanks of the bone screws.

{1}------------------------------------------------

030372 Page 2of2

- 5. Intended Use: The EBI® DynaFix® Diaphyseal Correction System is intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.
- 6. Materials: The components of the System may be manufactured from materials such as titanium, stainless steel, aluminum, and Delrin®.
- 7. Comparison of the technological characteristics of the device to predicate

devices: There are no significant differences between the EBI® DynaFix® Diaphyseal Correction System and other currently marketed external fixation systems. It is substantially equivalent* to the predicate device in regards to intended use, materials, and function.

<sup>*</sup> Any statement made in conjunction with this submission regarding a determination of substantial equivalence to any other product is intended only to relate the product can be lawfully marketed without pre-market approval or reclassification and is not interpreted as an admission or any other type of evidence in patent infringement litigation. [Establishment Registration and Premarket Notification Procedures, Final Regulation, Preamble, August 23, 1977, FR 42520 (Docket No. 76N-0355.)]

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight, with three stylized lines forming the wings and a profile of a human face incorporated into the design.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 0 6 2003

Mr. Frederick Testa Senior Regulatory Affairs Specialist EBI. L.P. 100 Interpace Parkway Parsippany, New Jersey 07054

Re: K030372

Trade Name: EBI® DynaFix® Diaphyseal Correction System Regulation Number: 21 CFR 888.3030 Regulation Name: Single/multiple component metallic bone fixation appliances and accessories Regulatory Class: II Product Code: KTT Dated: February 3, 2003 Received: February 4, 2003

Dear Mr. Testa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 -- Mr. Frederic Testa

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely vours,

Sincerely yours,

Mark A. Milken

Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## STATEMENT OF INDICATIONS FOR USE

Page 1 of of le

510(k) Number (if known): k030372

Device Name: EBI® DynaFix® Diaphyseal Correction System

Indications For Use:

The EBI® DynaFix® Diaphyseal Correction System is a unilateral external fixation device intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.

## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use_ (Per 21 CFR 801.109) OR

Over-The-Counter Use

(Optional Format 1-2-96)
Mark N Millerson

Division of Occeral, Restorative and Neurological Devices

510(k) Number _

---

**Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KTT/K030372](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KTT/K030372)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com
